Management of women with Gaucher disease in the reproductive age

• Published in: Thrombosis research 2015-02, Vol.135, p.S49-S51
• Main Author: Rosenbaum, Hanna
• Format: Article
• Language: English
• Subjects: Enzyme Replacement Therapy - methods; Female; Females; Gaucher disease (GD); Gaucher Disease - diagnosis; Gaucher Disease - drug therapy; Hematology, Oncology and Palliative Medicine; Humans; Pregnancy; Pregnancy Complications, Cardiovascular - diagnosis; Pregnancy Complications, Cardiovascular - drug therapy; Pregnancy Outcome; Treatment Outcome
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/S0049-3848(15)50443-X

ABSTRACT Gaucher disease (GD) is a lysosomal disorder caused by inherited deficiency of glucocerebrosidase, resulting in the accumulation of glucocerebroside in macrophages, termed “Gaucher cells” (GCs), leading to multiorgan involvement, with hepatosplenomegaly, cytopenias, pulmonary hypertension and osseous complications. The characteristic feature of GD is the organ GCs infiltration compromising their function by inducing local inflammation, infarcts and fibrosis. Enzyme replacement therapy (ERT) available for over two decades improves hematological abnormalities, reverses the visceromegaly, ameliorates bone symptoms and prevents further skeletal complications. GD affects most female events during the reproductive age, particularly, fertility, pregnancy, delivery and puerperium. While pregnancy in GD may exacerbate disease manifestations, the disease may have deleterious effect on female reproductive health milestones. ERT has a beneficial effect on the pregnancy outcome in terms of the risk of spontaneous abortion and GD-related complications, particularly bleeding during delivery and postpartum. Treatment approaches and management aspects of reproductive age events are reviewed hereby, with a focus on the outcome improvement of pregnancies, deliveries and postpartum period in GD patients.